{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:03:14Z","timestamp":1764403394891,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"INSERM\/CNRS ATIP-Avenir","award":["ANR-10-LABX-006","FDM202006011181"],"award-info":[{"award-number":["ANR-10-LABX-006","FDM202006011181"]}]},{"name":"Laboratory of Excellence (LabEx) Dev2Can","award":["ANR-10-LABX-006","FDM202006011181"],"award-info":[{"award-number":["ANR-10-LABX-006","FDM202006011181"]}]},{"name":"Fondation pour la Recherche M\u00e9dicale","award":["ANR-10-LABX-006","FDM202006011181"],"award-info":[{"award-number":["ANR-10-LABX-006","FDM202006011181"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is a B-cell-derived hematologic malignancy whose progression depends on active B-cell receptor (BCR) signaling. Despite the spectacular efficacy of Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), resistance can develop in CLL patients, and alternative therapeutic strategies are therefore required. Cancer immunotherapy has revolutionized cancer care and may be an attractive approach in this context. We speculated that characterizing the immune responses of CLL patients may highlight putative immunotherapeutic targets. Here, we used high-dimensional spectral flow cytometry to compare the distribution and phenotype of non-B-cell immune populations in the circulating blood of CLL patients treated with Ibrutinib displaying a complete response or secondary progression. Although no drastic changes were observed in the composition of their immune subsets, the Ibrutinib-resistant group showed increased cycling of CD8+ T cells, leading to their overabundance at the expense of dendritic cells. In addition, the expression of 11 different surface checkpoints was similar regardless of response status. Together, this suggests that CLL relapse upon Ibrutinib treatment may not lead to major alterations in the peripheral immune response.<\/jats:p>","DOI":"10.3390\/cells13171458","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T09:39:32Z","timestamp":1725010772000},"page":"1458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib"],"prefix":"10.3390","volume":"13","author":[{"given":"Pierre","family":"St\u00e9phan","sequence":"first","affiliation":[{"name":"Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Universit\u00e9 Claude Bernard Lyon 1, Labex DEV2CAN, Centre L\u00e9on B\u00e9rard, 69008 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0625-9040","authenticated-orcid":false,"given":"Khaled","family":"Bouherrou","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Universit\u00e9 Claude Bernard Lyon 1, Labex DEV2CAN, Centre L\u00e9on B\u00e9rard, 69008 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Guillermin","sequence":"additional","affiliation":[{"name":"Hematology Department-Centre L\u00e9on B\u00e9rard, 69008 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Michallet","sequence":"additional","affiliation":[{"name":"Hematology Department-Centre L\u00e9on B\u00e9rard, 69008 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-8305","authenticated-orcid":false,"given":"Yenkel","family":"Grinberg-Bleyer","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Universit\u00e9 Claude Bernard Lyon 1, Labex DEV2CAN, Centre L\u00e9on B\u00e9rard, 69008 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Arruga, F., Gyau, B.B., Iannello, A., Vitale, N., Vaisitti, T., and Deaglio, S. (2020). Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051825"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"key":"ref_5","first-page":"52","article-title":"Regulatory T-cells in chronic lymphocytic leukemia: Actor or innocent bystander?","volume":"3","author":"Simeon","year":"2013","journal-title":"Am. J. Blood Res."},{"key":"ref_6","first-page":"677","article-title":"Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia","volume":"20","author":"Giannopoulos","year":"2008","journal-title":"Oncol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41375-018-0250-6","article-title":"Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sportoletti, P., de Falco, F., del Papa, B., Baldoni, S., Guarente, V., Marra, A., Dorillo, E., Rompietti, C., Adamo, F.M., and Ruggeri, L. (2021). NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136665"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1330235","DOI":"10.1080\/2162402X.2017.1330235","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"MacFarlane","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1097\/HS9.0000000000000308","article-title":"Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling","volume":"3","author":"Hofland","year":"2019","journal-title":"Hemasphere"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","article-title":"Overcoming resistance to targeted therapies in chronic lymphocytic leukemia","volume":"5","author":"Skanland","year":"2021","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106520","DOI":"10.1016\/j.leukres.2021.106520","article-title":"Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia","volume":"102","author":"Solman","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mhibik, M., Wiestner, A., and Sun, C. (2019). Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010068"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.2023020554","article-title":"Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: Immune monitoring from the E1912 trial","volume":"143","author":"Papazoglou","year":"2024","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stephan, P., Perrot, J., Voisin, A., Barbery, M., Andrieu, T., Grimont, M., Caramel, J., Bardou, M., Tondeur, G., and Missiaglia, E. (2024). Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets. Haematologica.","DOI":"10.3324\/haematol.2023.284448"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2023.06.007","article-title":"Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia","volume":"34","author":"Cass","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/CJI.0000000000000345","article-title":"Checkpoint Blockade in Melanoma Patients with Underlying Chronic Lymphocytic Leukemia","volume":"44","author":"Smithy","year":"2021","journal-title":"J. Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Perutelli, F., Jones, R., Griggio, V., Vitale, C., and Coscia, M. (2022). Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.837531"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pula, B., Golos, A., Gorniak, P., and Jamroziak, K. (2019). Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11121834"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cadot, S., Valle, C., Tosolini, M., Pont, F., Largeaud, L., Laurent, C., Fournie, J.J., Ysebaert, L., and Quillet-Mary, A. (2020). Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: Evolution of leukemic and immune cells at relapse. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00253-w"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/jleuko\/qiad006","article-title":"Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansion","volume":"113","author":"Loizon","year":"2023","journal-title":"J. Leukoc. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wu, X., Fajardo-Despaigne, J.E., Zhang, C., Neppalli, V., Banerji, V., Johnston, J.B., Gibson, S.B., and Marshall, A.J. (2021). Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.674492"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1158\/1078-0432.CCR-22-2955","article-title":"Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed\/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma","volume":"29","author":"Chavez","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: Analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/curroncol29050293","article-title":"CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings","volume":"29","author":"Todorovic","year":"2022","journal-title":"Curr. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/17\/1458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:45:52Z","timestamp":1760111152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/17\/1458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":32,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cells13171458"],"URL":"https:\/\/doi.org\/10.3390\/cells13171458","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}